Crinetics Pharmaceuticals Inc. | Mid-cap | Healthcare
$29.06
-2.48%
| Crinetics Stock Comparison:
Crinetics vs VertexCrinetics vs RegeneronCrinetics vs Blueprint MedicinesCrinetics vs Roivant SciencesCrinetics vs Bio-TechneCrinetics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 1.0M
Operating Income -338.9M -32,613.47%
Net Income -298.4M -28,720.69%
EPS (Diluted) -$3.69

Balance Sheet Metrics

Total Assets 1.4B
Total Liabilities 109.8M
Shareholders Equity 1.3B
Debt to Equity 0.08

Cash Flow Metrics

Operating Cash Flow -205.6M
Free Cash Flow -229.8M

Revenue & Profitability Trend

Crinetics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue1.0M4.0M4.7M1.1M0
Cost of Goods Sold-----
Gross Profit-----
Operating Expenses339.9M226.6M172.6M108.8M75.0M
Operating Income-338.9M-222.6M-167.9M-107.7M-75.0M
Pre-tax Income-298.4M-214.5M-163.9M-107.6M-73.8M
Income Tax-----
Net Income-298.4M-214.5M-163.9M-107.6M-73.8M
EPS (Diluted)-$3.69-$3.69-$3.15-$2.80-$2.42

Income Statement Trend

Crinetics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets1.4B574.2M345.2M344.7M177.5M
Non-Current Assets59.2M61.2M7.0M6.3M6.0M
Total Assets1.4B635.4M352.2M351.0M183.4M
Liabilities
Current Liabilities59.7M43.9M27.7M16.0M10.5M
Non-Current Liabilities50.1M52.3M8.1M3.1M4.0M
Total Liabilities109.8M96.2M35.8M19.1M14.5M
Equity
Total Shareholders Equity1.3B539.1M316.3M331.9M168.9M

Balance Sheet Composition

Crinetics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-298.4M-214.5M-163.9M-107.6M-73.8M
Operating Cash Flow-205.6M-160.7M-115.9M-78.4M-58.2M
Investing Activities
Capital Expenditures-3.8M-4.7M-1.7M-436.0K-186.0K
Investing Cash Flow-574.8M-200.4M-174.0M-56.5M217.0K
Financing Activities
Dividends Paid-----
Financing Cash Flow970.0M369.0M117.2M249.5M114.3M
Free Cash Flow-229.8M-171.0M-116.9M-89.0M-62.2M

Cash Flow Trend

Crinetics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -8.43
Forward P/E -7.75
Price to Book 2.23
Price to Sales 3,717.62
PEG Ratio -7.75

Profitability Ratios

Profit Margin 0.00%
Operating Margin -30,860.11%
Return on Equity -30.84%
Return on Assets -20.13%

Financial Health

Current Ratio 22.53
Debt to Equity 4.05
Beta 0.28

Per Share Data

EPS (TTM) -$3.80
Book Value per Share $13.41
Revenue per Share $0.01

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
crnx2.8B-8.432.23-30.84%0.00%4.05
Vertex 114.1B32.826.92-5.64%-8.91%10.00
Regeneron 55.3B13.021.8415.96%31.94%9.20
Blueprint Medicines 8.3B-120.0024.19-47.71%-27.70%208.50
Roivant Sciences 7.8B1.951.71-12.54%96.86%1.93
Bio-Techne 7.9B60.873.926.53%10.89%20.99

Financial data is updated regularly. All figures are in the company's reporting currency.